Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | GLS | O94925 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725815 | 0.87 | NAMPT (0.49) | DYRK1ASMN1; SMN2NAMPTHDAC1 | |
| SCHEMBL30504293 | 0.84 | HDAC1 (0.56) | BRD4CREBBPNAMPTGLSHDAC1 | |
| SCHEMBL301717 | 0.82 | PRMT6 (0.56) | BRD4CREBBPNAMPTGLSHDAC1 | |
| SCHEMBL29376317 | 0.82 | DYRK1A (0.56) | DYRK1ANAMPTHDAC1CYP3A4CTSB | |
| SCHEMBL20299920 | 0.82 | DYRK1A (0.56) | DYRK1ANAMPTHDAC1CYP3A4CTSB | |
| SCHEMBL13999418 | 0.81 | DYRK1A (0.49) | DYRK1ASMN1; SMN2NAMPTGLSHDAC1 | |
| SCHEMBL18664426 | 0.81 | HDAC1 (0.60) | BRD4CREBBPGLSHDAC1CTSB | |
| SCHEMBL5580792 | 0.81 | CTSB (0.46) | BRD4CREBBPGLSHDAC1CTSB | |
| SCHEMBL31357646 | 0.81 | CYP4F2 (0.36) | SMN1; SMN2CYP3A4CTSBCTSSCTSK | |
| SCHEMBL31357670 | 0.81 | CYP4F2 (0.36) | SMN1; SMN2CYP3A4CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | DYRK1A 1550/4885BRD4 1304/4885CREBBP 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.